Nifty Pharma Rises 0.40% for Fourth Straight Day on June 8, 2026 as Sun Pharma and Alkem Labs Gain Despite Broad Market Crash

Nifty Pharma 24,343.90 (+0.40%) June 8 2026. 4th straight gain. Sun Pharma Rs 1,797.90 (+0.88%). Alkem Rs 5,377.50 (+2.40%). Dr Reddy’s Rs 1,287.20 (+0.70%). 52W High 25,043.

Nifty Pharma extended its winning streak to four consecutive sessions on June 8, 2026, rising 0.40% to 24,343.90, even as the broader market fell and most sectoral indices closed in the red. Sun Pharma led the index with a 0.88% gain to Rs 1,797.90, followed by Alkem Laboratories with a strong 2.40% rise to Rs 5,377.50 and Dr Reddy’s Laboratories up 0.70% to Rs 1,287.20. The Nifty Pharma index has now outperformed virtually every other sectoral index across its four-day run.

The pharmaceutical sector’s resilience in today’s session, where multiple other indices fell 1-2% on crude oil and rate hike concerns, illustrates its structural defensive characteristics. Pharma demand is largely inelastic to geopolitical shocks, crude oil price spikes, and interest rate cycles, making it a preferred safe haven when macro headwinds intensify across cyclical sectors.

Click Here – Get Free Investment Predictions

Why Is Nifty Pharma Rising While the Broader Market Falls

Pharma as Defensive Safe Haven in a Crude and Rate Hike Shock

Nifty Pharma is rising for the fourth consecutive day because pharmaceutical demand is fundamentally insulated from the macro variables that are driving today’s broader market selloff. Crude oil at $97 directly hurts auto, paint, airline, and NBFC stocks through higher input costs, fuel costs, and borrowing cost pressures. But drug demand is non-discretionary: patients do not defer medications because crude oil prices are high or because the Federal Reserve might raise rates. This inelastic demand profile makes pharma one of the safest sectoral allocations during periods of macro turbulence like the current one driven by the US-Iran conflict.

Weak Rupee Benefits Indian Pharmaceutical Exporters

The Indian rupee is currently trading at approximately Rs 95.36 per dollar, weakened by FII selling and global risk-off sentiment. For Indian pharmaceutical companies, a weaker rupee is a direct revenue tailwind. Companies like Sun Pharma, Dr Reddy’s and Alkem generate significant portions of their revenue in USD (through US generic sales and international markets) and report in INR. Every dollar earned converts to more rupees, effectively boosting reported revenue and profitability for the full year without any operational change. This FX effect is one of the key reasons Nifty Pharma gains when FII-driven rupee weakness hits other sectors.

Sun Pharma Organon Acquisition Adds Long-Term Growth Visibility

Sun Pharma’s share price has benefited from the April 27, 2026 announcement of its agreement to acquire Organon, a global healthcare company formed from a Merck spinoff, in an all-cash deal valued at $11.75 billion ($14 per share). Organon has six manufacturing facilities across the EU and emerging markets, and the acquisition significantly expands Sun Pharma’s specialty medicines portfolio and international market reach. Sun Pharma reported strong Q4 FY26 results on May 22, 2026, with 13.6% sales growth, driven by its innovative medicines division and India business, further supporting the bull case for the stock within Nifty Pharma.

Alkem Laboratories Gains on Domestic Pharma Leadership

Alkem Laboratories is the standout Nifty Pharma performer today, rising 2.40% to Rs 5,377.50 on strong volume. Alkem has established leadership in India’s acute therapy segments (anti-infectives, gastrointestinal, pain management) and has been expanding its chronic therapy portfolio. The company’s India-centric revenue model provides insulation from US generic pricing pressures that affect some of its larger peers. Alkem’s strong domestic market share in branded generics and its improving US regulatory track record have made it a preferred defensive pick among institutional investors seeking pharmaceutical sector exposure.

Track Nifty Pharma Stocks Live and Access Pharma Sector Research on the Univest Screener

Sun Pharma and Dr Reddy’s Outlook: US Pipeline and Specialty Growth

Download the Univest iOS App or Univest Android App to track Nifty Pharma stocks live and receive pharmaceutical sector research alerts from Univest.

The near-term Nifty Pharma outlook remains constructive. Sun Pharma’s integration of the Organon acquisition will be the key earnings driver to watch for Q1 FY27, while the specialty medicines pipeline (ILUMYA, Winlevi) continues to deliver revenue diversification away from commoditised generics. Dr Reddy’s strong US generic portfolio and active biosimilar pipeline provide additional sector momentum. The FX tailwind from rupee weakness and the continuing USFDA approval pipeline (several Indian pharma companies received approvals in the June 5-8 period) collectively support the Nifty Pharma index’s fourth-day rally.

Conclusion

Nifty Pharma rose 0.40% to 24,343.90 on June 8, 2026, its fourth consecutive session of gains, making it one of the few sectoral bright spots in today’s broad market selloff. Sun Pharma (+0.88%), Alkem Labs (+2.40%) and Dr Reddy’s (+0.70%) led the advance. The pharma sector’s outperformance reflects its defensive, non-cyclical demand profile, a tailwind from rupee weakness, and company-specific catalysts including the Sun Pharma-Organon deal. Investors seeking defensive allocation during the current crude oil and rate hike uncertainty should evaluate the Nifty Pharma space. This article does not constitute investment advice.

Frequently Asked Questions on Nifty Pharma Today

Why is Nifty Pharma rising for the fourth straight day on June 8, 2026?

Ans. Nifty Pharma is rising for the fourth consecutive session on June 8, 2026, because the pharmaceutical sector is a defensive safe haven whose demand is inelastic to crude oil prices and interest rate changes. Sun Pharma gained 0.88%, Alkem Labs 2.40%, and Dr Reddy’s 0.70%, while cyclical sectors fell on Brent crossing $97 and Federal Reserve rate hike fears.

What is Sun Pharma share price today?

Ans. Sun Pharma share price is Rs 1,797.90 on June 8, 2026, up 0.88% from its previous close of Rs 1,782.20. The stock opened at Rs 1,780.70 and hit an intraday high of Rs 1,803.50. Sun Pharma is one of the key Nifty Pharma index gainers today, supported by the Organon acquisition catalyst and strong Q4 FY26 results. Verify the latest price at nseindia.com.

Why is Alkem Labs share price rising today?

Ans. Alkem Labs share price is rising 2.40% to Rs 5,377.50 on June 8, 2026, as the stock benefits from broad pharma sector defensive buying and its own strong domestic pharma market position. Alkem has leadership in acute therapy segments in India and a growing chronic portfolio. Its India-centric revenue model provides insulation from US generic pricing pressures affecting some peers.

What is Nifty Pharma index level today?

Ans. Nifty Pharma is at 24,343.90 on June 8, 2026, up 0.40% from the previous session. This is its fourth consecutive day of gains. The 52-week high for Nifty Pharma is 25,043.15 and the 52-week low is 21,149.90. The index has been one of the best-performing sectoral indices over the past four sessions. Verify the current level at nseindia.com.

Why does pharma sector gain when the rest of the market falls?

Ans. The pharmaceutical sector gains relative to cyclicals during broad market falls because drug demand is non-discretionary. Patients do not reduce medication use because of crude oil price spikes or interest rate changes. Additionally, a weaker rupee from FII outflows directly benefits pharmaceutical exporters by improving their USD-to-INR revenue conversion. These two factors make pharma a structural safe haven during macro turbulence.

What is the Sun Pharma Organon acquisition?

Ans. Sun Pharma agreed on April 27, 2026, to acquire Organon and Co., a global healthcare company spun off from Merck, in an all-cash deal valued at $11.75 billion ($14 per share). Organon has six manufacturing facilities across the EU and emerging markets and specialises in women’s health, biosimilars, and established branded medicines. The deal significantly expands Sun Pharma’s specialty portfolio and international presence.

How does a weak rupee help pharma stocks?

Ans. A weaker Indian rupee benefits pharmaceutical exporters because they generate revenue in US dollars and other foreign currencies but report in Indian rupees. When the rupee depreciates, the same dollar revenue converts to a higher rupee amount, boosting reported revenue and PAT without any change in operations. With the rupee around Rs 95.36 per dollar today, Indian pharma exporters like Sun Pharma and Dr Reddy’s get a meaningful FX tailwind.

Should I invest in Nifty Pharma stocks now?

Ans. This article does not constitute investment advice. While Nifty Pharma has shown strong defensive momentum over four sessions, investment decisions should be based on individual company fundamentals, valuation, pipeline visibility, and regulatory track record. Pharma stocks carry regulatory risks including US FDA inspections, patent cliffs, and pricing pressures. Consult a SEBI-registered financial advisor before making any investment decisions.